Ross C. Donehower

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 76 Citations 36,374 241 World Ranking 13686 National Ranking 7081

Overview

What are the main themes of his work throughout his whole career to date

His Epidermal growth factor receptor study focuses on Erlotinib and Gefitinib. Ross C. Donehower integrates many fields in his works, including Gefitinib and Epidermal growth factor receptor. He regularly links together related areas like Erlotinib in his Internal medicine studies. His Oncology study frequently draws parallels with other fields, such as Progression-free survival. His research is interdisciplinary, bridging the disciplines of Oncology and Progression-free survival. With his scientific publications, his incorporates both Gastroenterology and Urology. He brings together Urology and Gastroenterology to produce work in his papers. With his scientific publications, his incorporates both Cancer and Rash. In his works, Ross C. Donehower conducts interdisciplinary research on Rash and Cancer.

Ross C. Donehower most often published in these fields:

Internal medicine (100.00%)
Oncology (88.89%)
Gastroenterology (55.56%)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Dung T. Le;Jennifer N. Uram;Hao Wang;Bjarne R. Bartlett.
The New England Journal of Medicine (2015)

7547 Citations

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Dung T. Le;Dung T. Le;Jennifer N. Durham;Jennifer N. Durham;Kellie N. Smith;Hao Wang.
Science (2017)

4423 Citations

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms.

William P. McGuire;Eric K. Rowinsky;Neil B. Rosenshein;Francis C. Grumbine.
Annals of Internal Medicine (1989)

1616 Citations

Taxol: A Novel Investigational Antimicrotubule Agent

Eric K. Rowinsky;Lorranie A. Cazenave;Ross C. Donehower.
Journal of the National Cancer Institute (1990)

1533 Citations

Hypersensitivity reactions from taxol.

R B Weiss;R C Donehower;P H Wiernik;T Ohnuma.
Journal of Clinical Oncology (1990)

1479 Citations

Clinical toxicities encountered with paclitaxel (Taxol)

Rowinsky Ek;Eisenhauer Ea;Chaudhry;Arbuck Sg.
Seminars in Oncology (1993)

949 Citations

The Current Status of Camptothecin Analogues as Antitumor Agents

William J. Slichenmyer;Eric K. Rowinsky;Ross C. Donehower;Scott H. Kaufmann.
Journal of the National Cancer Institute (1993)

784 Citations

Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor–Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation

Elizabeth M. Jaffee;Ralph H. Hruban;Barbara Biedrzycki;Daniel Laheru.
Journal of Clinical Oncology (2001)

652 Citations

Phase II Study of Erlotinib (OSI-774) in Patients With Advanced Hepatocellular Cancer

Philip A. Philip;Michelle R. Mahoney;Cristine Allmer;James Thomas.
Journal of Clinical Oncology (2005)

649 Citations

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.

Dung T. Le;Eric Lutz;Jennifer N. Uram;Elizabeth A. Sugar.
Journal of Immunotherapy (2013)

523 Citations

If you think any of the details on this page are incorrect, let us know.